First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease

Trial Profile

First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs FLYSYN (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Acronyms FLYSYN-101
  • Most Recent Events

    • 13 Mar 2017 Time frame of primary endpoint has been changed from day 43 to until 28 days (i.e. Visit7, day 29) after last dosing.
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 08 Feb 2017 Planned number of patients changed from 19 to 28.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top